Amgen and Allergan announce FDA advisory committee meeting to review ADP 215, a biosimilar candidate to Bevacizumab

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Amgen and Allergan said the FDA Oncologic Drugs Advisory Committee will review data supporting the Biologics License Application for ABP 215, a biosimilar candidate to Avastin (bevacizumab), an agent sponsored by Genentech, a unit of Roche.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login